CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Jun 23, 2022 8:35am EDT
CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Jun 08, 2022 8:35am EDT
CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference May 24, 2022 7:00am EDT
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting May 18, 2022 8:35am EDT
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update May 16, 2022 8:05am EDT
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Apr 28, 2022 8:35am EDT
CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event Apr 12, 2022 8:35am EDT
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Apr 06, 2022 8:35am EDT
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Apr 05, 2022 8:35am EDT
CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest Mar 23, 2022 8:35am EDT
